PeptidePedia The community reference

Contributions of TrialsTabitha

User contributions·55 logged edits·page 1 of 1

Contributions by TrialsTabitha, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 21,455 edits includes activity predating the current log.

  1. 00:26, 26 Jul 2026 (diff | hist) Sharps disposal 20,876 ±0 m the example withdrew more than the syringe holds; corrected
  2. 10:12, 20 Jul 2026 (diff | hist) Asymchem Laboratories 1,789 +1,789 N start organisation article — registry facts and product scope only
  3. 17:54, 23 Jun 2026 (diff | hist) Shanghai Sigma-Audley New Material Technology 15,579 ±0 attribute the capability claim to the organisation's own material
  4. 02:32, 14 Jun 2026 (diff | hist) Sharps disposal 16,335 +363 state the syringe graduation the unit figure assumes
  5. 00:25, 30 May 2026 (diff | hist) ChinaPeptides 14,979 ±0 add the lead time for catalogue lines, as reported
  6. 14:35, 21 May 2026 (diff | hist) Talk:Dulaglutide 748 +152 /* REWIND population */ reply
  7. 13:15, 11 May 2026 (diff | hist) Talk:SUSTAIN trial programme 748 +104 /* Dose confusion with STEP */ reply
  8. 19:29, 8 May 2026 (diff | hist) PolyPeptide Group (Hangzhou) 18,363 ±0 attribute the capability claim to the organisation's own material
  9. 09:15, 7 May 2026 (diff | hist) Talk:Trial data comparison 822 +256 /* Cross-trial tabulation and the estimand problem */ reply
  10. 17:19, 19 Feb 2026 (diff | hist) Missed dose 5,277 ±0 m rm a duplicated category
  11. 13:42, 19 Feb 2026 (diff | hist) Talk:Tirzepatide 611 +141 /* SURPASS-2 comparator dose */ reply
  12. 15:26, 12 Feb 2026 (diff | hist) Intention-to-treat analysis 4,963 ±0 add the PMID
  13. 17:56, 10 Feb 2026 (diff | hist) TRIUMPH trial programme 4,703 ±0 m correct the baseline mean — transposed digits
  14. 13:10, 8 Feb 2026 (diff | hist) Talk:STEP trial programme 611 +109 /* Escalation inside the trial duration */ reply
  15. 01:44, 3 Jan 2026 (diff | hist) Placebo-adjusted effect 4,805 ±0 m add the missing-data handling method
  16. 13:53, 22 Dec 2025 (diff | hist) Peptide harm reduction 4,800 ±0 expand §What the uncertainties are
  17. 12:34, 19 Dec 2025 (diff | hist) Amylin 5,795 ±0 m expand §Receptors
  18. 02:36, 5 Dec 2025 (diff | hist) SELECT trial 5,171 ±0 expand §Results and their interpretation
  19. 01:08, 20 Nov 2025 (diff | hist) STEP trial programme 5,534 ±0 add the confidence interval to the point estimate
  20. 18:15, 15 Nov 2025 (diff | hist) PolyPeptide Group (Hangzhou) 10,342 +724 rm a duplicated category
  21. 16:01, 13 Nov 2025 (diff | hist) Janoshik Analytical 5,235 ±0 label the community tally as self-reported at this point of use as well
  22. 16:02, 13 Oct 2025 (diff | hist) Talk:Trial data comparison 885 +230 /* Head-to-head filter: is the flag applied consistently? */ reply
  23. 12:20, 22 Sep 2025 (diff | hist) Albumin binding half-life extension 6,399 ±0 add see also to the sister hormone
  24. 06:12, 16 Sep 2025 (diff | hist) Hunan Aslsen Technology 13,388 +480 serial comma per PP:MOS
  25. 10:59, 9 Sep 2025 (diff | hist) Fmoc chemistry 4,618 ±0 expand §Characteristic side reactions
  26. 22:14, 2 Sep 2025 (diff | hist) Multi-dose vial 20,489 +1,753 clarify that the figure is per dose, not per vial
  27. 11:03, 21 Aug 2025 (diff | hist) Drug master file 4,325 +233 attribute the compounding statement to the pharmacy board that issued it
  28. 10:51, 21 Aug 2025 (diff | hist) Customs seizure 4,516 ±0 correct the description of the research-use-only exemption
  29. 19:36, 14 Jul 2025 (diff | hist) Qingdao Sigma Chemical 12,870 +810 correct the regional-warehouse list — six sites, not five
  30. 21:25, 23 Jun 2025 (diff | hist) Peptide harm reduction 3,975 ±0 state the exchange rate and its date
  31. 14:00, 15 Jun 2025 (diff | hist) CagriSema 4,185 +18 add see also to the amylin analogue
  32. 18:31, 26 Apr 2025 (diff | hist) Wuhan Wansheng Biotechnology 10,999 +746 attribute the capability claim to the organisation's own material
  33. 02:11, 23 Apr 2025 (diff | hist) Active pharmaceutical ingredient 3,553 ±0 m unpipe a link that did not need piping
  34. 06:52, 16 Apr 2025 (diff | hist) ISO 9001 3,340 ±0 typo
  35. 16:56, 12 Apr 2025 (diff | hist) Deamidation 4,219 ±0 add the ionisation mode to the mass-spectrometry description
  36. 07:48, 4 Apr 2025 (diff | hist) Lyophilisation 20,027 +147 m attribute the stability figure to the study and its duration
  37. 08:59, 2 Apr 2025 (diff | hist) SELECT trial 4,206 ±0 m add the DOI
  38. 21:58, 5 Mar 2025 (diff | hist) LEADER trial 3,537 ±0 rm the survival claim — no mortality endpoint was pre-specified
  39. 11:07, 28 Feb 2025 (diff | hist) Glucose-dependent insulinotropic polypeptide 6,686 ±0 copyedit
  40. 08:18, 26 Feb 2025 (diff | hist) Hunan Aslsen Technology 7,721 ±0 expand §Ordering and availability
  41. 14:22, 24 Feb 2025 (diff | hist) Amylin 4,252 +296 reorder the analogues chronologically rather than alphabetically
  42. 10:31, 2 Feb 2025 (diff | hist) SUSTAIN trial programme 4,169 ±0 expand §SUSTAIN 6 and its interpretation
  43. 04:29, 17 Jan 2025 (diff | hist) GL Biochem (Shanghai) 9,579 +110 expand §Operations and documentation practice
  44. 15:35, 14 Jan 2025 (diff | hist) Patent expiry and biosimilars 2,578 +736 m add the citation for the regulatory action
  45. 08:37, 18 Dec 2024 (diff | hist) Dual incretin agonist 4,571 +124 correct the molar mass — source gives the free-base figure, we had the salt
  46. 16:33, 16 Nov 2024 (diff | hist) Electrospray ionisation 2,601 +34 fix the anchor on an internal link
  47. 22:09, 14 Nov 2024 (diff | hist) Chain of custody 2,966 ±0 m correct the description of the sampling procedure
  48. 23:29, 5 Nov 2024 (diff | hist) SURPASS trial programme 3,627 +1,016 state that the trial has reported but is not yet peer-reviewed
  49. 21:12, 24 Oct 2024 (diff | hist) Drug master file 1,551 ±0 expand §What a DMF claim establishes
  50. 20:17, 8 Oct 2024 (diff | hist) Intention-to-treat analysis 2,691 +31 the trial was open-label; the article implied blinding
  51. 17:50, 4 Oct 2024 (diff | hist) Peptide supply chain 1,378 +1,378 N start article on the process step
  52. 17:08, 4 Oct 2024 (diff | hist) SURPASS trial programme 2,611 ±0 rm a duplicated category
  53. 05:00, 10 Sep 2024 (diff | hist) Good manufacturing practice 1,773 +620 expand §What a GMP claim on a research chemical means
  54. 09:00, 15 Aug 2024 (diff | hist) Retention time 986 +986 N new article: analytical method, expansion welcome
  55. 16:43, 9 Jul 2024 (diff | hist) Proglucagon 1,868 +372 add category for receptor pharmacology